bioAffinity Technologies to Present CyPath Lung Data at CHEST 2026
bioAffinity Technologies, Inc. (BIAF) announced it will sponsor a Learning Theater presentation on October 21 at the CHEST 2026 conference. The session will focus on the clinical application of CyPath Lung, a noninvasive diagnostic tool designed to aid in lung cancer risk assessment and pulmonary nodule management. The presentation will also highlight positive research results for an experimental diagnostic test targeting lung inflammation related to asthma and chronic obstructive pulmonary disease.
CyPath Lung uses flow cytometry and artificial intelligence to analyze sputum samples. In previous clinical testing, the diagnostic test demonstrated a 92% sensitivity rate, an 87% specificity rate, and a 99% negative predictive value. Demonstrating the diagnostic utility of CyPath Lung and introducing additional diagnostic tools for chronic respiratory conditions could strengthen the company's product offerings in pulmonary health.
Investors should monitor the upcoming CHEST 2026 event for detailed clinical findings and updates on the company's growth strategy. Additionally, the company's Medical and Scientific Advisory Board will gather during the conference to discuss expanding CyPath Lung, conducting a longitudinal study, and advancing overall research and development initiatives. Shares of bioAffinity Technologies were trading down 1.79% at $3.56 following the announcement.
Key points
- bioAffinity Technologies, Inc. (BIAF) will sponsor a presentation on CyPath Lung at the CHEST 2026 conference on October 21.
- The presentation will share research data on an investigational diagnostic test for asthma and COPD lung inflammation.
- Prior clinical trial results for CyPath Lung showed 92% sensitivity, 87% specificity, and a 99% negative predictive value.
- The company's advisory board will meet at CHEST 2026 to discuss CyPath Lung expansion and a prospective longitudinal study.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is bioAffinity Technologies presenting at CHEST 2026?
bioAffinity Technologies will sponsor a presentation on October 21 at CHEST 2026 covering the clinical use of CyPath Lung in lung cancer risk stratification, as well as positive research data for a new asthma and COPD lung inflammation test.
How accurate is the CyPath Lung test according to clinical data?
In prior trial results, CyPath Lung demonstrated a 92% sensitivity, an 87% specificity, and a 99% negative predictive value as a noninvasive, sputum-based AI and flow cytometry test.
What will bioAffinity Technologies' advisory board discuss at the event?
The Medical and Scientific Advisory Board will meet at CHEST 2026 to discuss CyPath Lung expansion, a longitudinal study, and other research and development programs.